Wockhardt gets USFDA's approval for Sertraline Hydrochloride

Ahmedabad, Jan 9 (UNI) Pharmaceutical and biotechnology major Wockhardt has received an approval from the US Food and Drug Administration for marketing the Sertraline Hydrochloride tablets used for treating depression.

With over a dozen new product launches in the last twelve months and the recent acquisition of Morton Grove Pharmaceuticals, Wockhardt's US business has been making significant progress, according to Wockhardt Chairman Habil Khorakiwala.

''We are continuing to strengthen the US operations by filing several ANDAs, including technologically challenging products,'' Mr Khorakiwalla said in a statement here.

Wockhardt's Sertraline tablets will be launched in the US market within the next few weeks. The total market for Sertraline tablets in the US is 1.1 billion dollar equivalent to over 1.4 billion tablets. Wockhardt has been consistently growing market shares for all its products and today markets over fifty products in the US.

The Sertraline tablets are manufactured at the US FDA certified formulation plant at Waluj in Maharashtra. Wockhardt is one of the few companies with end-to-end integrated capabilities for its products, starting with manufacture of the oral and sterile API's, the dose forms and marketing through the wholly-owned subsidiary in the US, enabling the company to capture maximum value.

UNI PVN MAZ SR BD2032